Innovative drug stocks plummeted in early trading on the Hong Kong stock market, with declines exceeding 6% in the oncology, assisted reproductive, innovative drug, and CXO sectors. A-share innovative drug stocks also followed suit, with BeiGene and Innovent Biologics falling over 10%, and Sinopharm, Huahai Pharmaceutical, Chipscreen Biopharma, Rongchang Biopharma, and WuXi AppTec dropping over 6%. Despite negative market news, research institutions strongly advocated for the sell-off, viewing it as a buying opportunity. They also believed that the upward trend in the A-share and Hong Kong pharmaceutical sectors is far from over, and that the main upward trend is expected to continue in the medium to long term. News reports circulated across investment circles that the Trump administration is considering strict restrictions on pharmaceuticals imported from China, including a draft executive order that could disrupt experimental therapies invented in China, potentially impacting the US pharmaceutical industry and limiting the availability of generic drugs and advanced therapies. However, the White House stated that it was not "actively considering" the draft order.